Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.Completed
NCT01924533Phase 3Updated Mar 22, 2024
Sponsor: AstraZeneca
Gastric Cancer
China, Japan, South Korea, Taiwan
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerCompleted
NCT02735239Phase 1, Phase 2Updated Mar 22, 2024
Sponsor: Ludwig Institute for Cancer Research
Esophageal Cancer
United Kingdom
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLCCompleted
NCT02337530Phase 2Updated Mar 21, 2024
Sponsor: Canadian Cancer Trials Group
Non-Small Cell Lung Cancer
Canada
Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world DataUnknown
NCT06314542N/AUpdated Mar 18, 2024
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
China
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic AcidCompleted
NCT00295646Phase 3Updated Mar 15, 2024
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
Austria, Germany
Efficacy and Safety of Dapagliflozin in Acute Heart FailureCompleted
NCT04298229Phase 3Updated Mar 15, 2024
Sponsor: Vanderbilt University Medical Center
Heart Failure · Diabetes Mellitus, Type 2
United States
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)Terminated
NCT04612725Phase 2Updated Mar 13, 2024
Sponsor: AstraZeneca
Chronic Spontaneous Urticaria
United States, Bulgaria, Germany, Japan, Poland +2 more
OREIOS International StudyCompleted
NCT05239507N/AUpdated Mar 13, 2024
Sponsor: AstraZeneca
Hepatocellular Carcinoma
Brazil, Egypt, Hong Kong, India, Kuwait +6 more
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19Terminated
NCT05084755N/AUpdated Mar 12, 2024
Sponsor: AstraZeneca
Prevention of Infectious Disease Caused by SARS-CoV-2
Japan
Treatment of Lung Adenocarcinoma With Bronchioloalveolar FeatureCompleted
NCT00198380Phase 2Updated Mar 8, 2024
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Pneumonic-type Adenocarcinoma (P-ADC) · Lung Adenocarcinoma With Bronchiolo-alveolar Feature
France
Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart FailureRecruiting
NCT05859048NAUpdated Mar 7, 2024
Sponsor: Cardiology Research UBC
Heart Failure
Canada
A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of LifeCompleted
NCT04034992N/AUpdated Mar 6, 2024
Sponsor: AstraZeneca
Chronic Kidney Disease
United States, Italy, Japan, Spain, Sweden +1 more
Faslodex in McCune-Albright SyndromeCompleted
NCT00278915Phase 2Updated Mar 5, 2024
Sponsor: AstraZeneca
Puberty, Precocious · McCune-Albright Syndrome
United States, France, Germany, Italy, Russia +1 more
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism SubjectsCompleted
NCT02981966Phase 4Updated Mar 4, 2024
Sponsor: The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
United States
T790M Plasma Testing Methodology Comparison and Clinical ValidationCompleted
NCT02997501Phase 3Updated Mar 4, 2024
Sponsor: AstraZeneca
Lung Cancer
China
A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.Completed
NCT05630677Phase 1Updated Mar 4, 2024
Sponsor: AstraZeneca
Healthy Volunteers
United States
Study of AZD1222 for the Prevention of COVID-19 in JapanCompleted
NCT04568031Phase 1, Phase 2Updated Mar 1, 2024
Sponsor: AstraZeneca
COVID-19
Japan
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)Terminated
NCT02605616Phase 2Updated Mar 1, 2024
Sponsor: University of Alabama at Birmingham
Non-alcoholic Fatty Liver Disease (NAFLD) · Non-alcoholic Steatohepatitis (NASH)
United States
Real World Study With Benralizumab in Severe Asthma in SwitzerlandCompleted
NCT03907137N/AUpdated Feb 29, 2024
Sponsor: AstraZeneca
Severe Eosinophilic Asthma
Switzerland
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 DiabetesCompleted
NCT02962492NAUpdated Feb 29, 2024
Sponsor: University at Buffalo
Evaluate Ketogenic Stress
United States
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyActive Not Recruiting
NCT04392505Phase 2Updated Feb 29, 2024
Sponsor: Oslo University Hospital
Cancer · Non Small Cell Lung Cancer · Non Small Cell Lung Cancer Stage III · NSCLC
Estonia, Finland, Lithuania, Norway
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)Completed
NCT03979313Phase 3Updated Feb 28, 2024
Sponsor: AstraZeneca
Respiratory Syncytial Virus Infections
United States, Argentina, Australia, Austria, Belgium +26 more
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)Completed
NCT03189875N/AUpdated Feb 28, 2024
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States, Australia, Canada, France, Germany +3 more
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtibUnknown
NCT03865511Phase 2Updated Feb 28, 2024
Sponsor: Nantes University Hospital
Non-small Cell Lung Cancer
France
Chemo-free BRCA-targeted Neoadjuvant StrategyWithdrawn
NCT05209529Phase 2Updated Feb 23, 2024
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
TNBC - Triple-Negative Breast Cancer · BRCA1 Mutation · BRCA2 Mutation

Previous page Next page